Water Tractor 673623C92 Pump + 100 HYDRO 86 HYDRO 70 HYDRO IH Case International Farm Implement Parts


  1. Home
  2. Water Tractor 673623C92 Pump + 100 HYDRO 86 HYDRO 70 HYDRO IH Case International
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
673623C92 Tractor Water Pump International Case IH HYDRO 70 HYDRO 86 HYDRO 100 +
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Brand:

Aftermarket

Model:

(HYDRO 100, 3688, 986, All w/ D436 Eng)

MPN:

673623C92

Model 1: (HYDRO 70, HYDRO 86, 666, 686, All w/ D312 Eng) WN-673623C92: 673623C92
Model 2: 1440, (766, 886, All w/ D360 Eng), 815, 966 Compatible Equipment Type: Tractor
Part Type: Water Pump Compatible Equipment Make: Case IH, International
UPC:

Does not apply

published on tue nov 09 2021

Water Tractor 673623C92 Pump + 100 HYDRO 86 HYDRO 70 HYDRO IH Case International Farm Implement Parts

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Water Tractor 673623C92 Pump + 100 HYDRO 86 HYDRO 70 HYDRO IH Case International Farm Implement Parts

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS